Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fe… Read more
Cumberland Pharmaceuticals Inc (CPIX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.007x
Based on the latest financial reports, Cumberland Pharmaceuticals Inc (CPIX) has a cash flow conversion efficiency ratio of 0.007x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($187.18K) by net assets ($25.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cumberland Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Cumberland Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cumberland Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cumberland Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Daesung Holdin
KO:016710
|
-0.019x |
|
Dominari Holdings Inc.
NASDAQ:DOMH
|
-0.023x |
|
Gyeongnam Steel Co. Ltd
KQ:039240
|
0.037x |
|
Offerpad Solutions Inc
NYSE:OPAD
|
1.003x |
|
Osangjaiel Co. Ltd
KQ:053980
|
0.010x |
|
HERITAGE GLOBAL DL-007
F:LGC
|
N/A |
|
Manaksia Coated Metals & Industries Limited
NSE:MANAKCOAT
|
-0.045x |
|
Thai Reinsurance Public Company Limited
BK:THRE
|
0.050x |
Annual Cash Flow Conversion Efficiency for Cumberland Pharmaceuticals Inc (2005–2024)
The table below shows the annual cash flow conversion efficiency of Cumberland Pharmaceuticals Inc from 2005 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $22.55 Million | $-612.19K | -0.027x | -113.04% |
| 2023-12-31 | $29.26 Million | $6.09 Million | 0.208x | -11.37% |
| 2022-12-31 | $35.97 Million | $8.45 Million | 0.235x | +57.84% |
| 2021-12-31 | $42.60 Million | $6.34 Million | 0.149x | +28.87% |
| 2020-12-31 | $46.87 Million | $5.42 Million | 0.116x | +93.09% |
| 2019-12-31 | $51.09 Million | $3.06 Million | 0.060x | +6.81% |
| 2018-12-31 | $55.57 Million | $3.11 Million | 0.056x | +742.00% |
| 2017-12-31 | $63.92 Million | $-557.71K | -0.009x | -212.03% |
| 2016-12-31 | $73.12 Million | $569.48K | 0.008x | -89.82% |
| 2015-12-31 | $76.82 Million | $5.88 Million | 0.077x | -7.70% |
| 2014-12-31 | $80.75 Million | $6.69 Million | 0.083x | +780.86% |
| 2013-12-31 | $79.29 Million | $746.13K | 0.009x | -88.72% |
| 2012-12-31 | $85.57 Million | $7.14 Million | 0.083x | -20.81% |
| 2011-12-31 | $82.84 Million | $8.72 Million | 0.105x | +2260.53% |
| 2010-12-31 | $77.72 Million | $346.66K | 0.004x | -20.45% |
| 2009-12-31 | $72.22 Million | $404.97K | 0.006x | -98.46% |
| 2008-12-31 | $17.55 Million | $6.40 Million | 0.364x | -29.26% |
| 2007-12-31 | $16.75 Million | $8.63 Million | 0.515x | +164.95% |
| 2006-12-31 | $11.13 Million | $2.16 Million | 0.194x | -49.83% |
| 2005-12-31 | $6.23 Million | $2.42 Million | 0.388x | -- |